Industry & Business

Construction to start on GCP2 Production Facility at Takeda Ireland Ltd site

 Breaking News
  • Engineering Business Camlin to Create Almost 300 Jobs in £28 Million Investment Engineering business, Camlin is creating 298 high value jobs as part of a £28 million expansion at its Lisburn headquarters. Camlin develops and supplies innovative engineering solutions, primarily for the electricity and rail industries. Speaking at the official opening of its new state-of-the-art factory, Invest Northern Ireland Chief Executive, Alastair Hamilton said: “Camlin is a high-tech [...]...
  • Ireland’s Nation Brand Booming – Brand Finance Report Ireland’s nation brand continues to be one of the fastest-growing in the world, rising 26% in value year on year to US$538 billion, according to the latest Brand Finance Nation Brands report. Jumping six places in the ranking, Ireland has broken into the top 30, growing faster than the USA, China or the UK. This [...]...
  • MSD Announces New Manufacturing Facility and 170 New Jobs For Carlow MSD, known as Merck in the US and Canada, has announced that it will construct a second manufacturing facility at its existing site in Carlow with the creation of 170 new jobs. The new facility will focus on the production of vaccines and biologics and is scheduled to commence manufacturing operations in 2023. The build will include an [...]...
  • €100 Million Investment For Four Capital Developments at Trinity College Dublin Teaching, research and student accommodation at Trinity College Dublin will be transformed over the next two years with the backing of a €100 million long-term European Investment Bank (EIB) loan for four capital developments across the campus. This will include the flagship E3-Engineering, Environment and Emerging Technologies initiative at Trinity. Central to the vision of E3 [...]...
  • SSE Airtricity and Verde LED Light the Way to Energy Savings in New Partnership SSE Airtricity, Ireland’s leading provider of 100% green energy, has announced a new exclusive partnership with Verde LED to provide LED lighting upgrades and energy-efficiency improvements to businesses across Ireland. Verde LED, founded in 2010, specialises in lighting design for new and existing facilities, with a dedicated research and development (R&D) department to ensure product [...]...

Construction to start on GCP2 Production Facility at Takeda Ireland Ltd site

Construction to start on GCP2 Production Facility at Takeda Ireland Ltd site
June 01
09:00 2017

Takeda Pharmaceutical Company Limited has announced that a groundbreaking ceremony has been held for its new production facility at the existing Grange Castle site in Ireland. Takeda’s existing footprint at the Grange Castle site will be expanded with the construction of a new standalone, high-containment production facility dedicated to manufacturing its oncology product NINLARO for global markets. The investment will create approximately 40 new jobs over the next two years.

“Our new plant in Grange Castle, Ireland is a strategic investment for Takeda,” said Thomas Wozniewski, Head of Global Manufacturing & Supply. “It will give us the crucial in-house manufacturing capacity to meet the increasing demand for our innovative product NINLARO.”

The construction of the plant, which begins in June 2017, will be managed by Project Management Group with over €40 million investment in total. The plant is scheduled to be completed in Q2 FY18 and become operational to commence shipment of secondary packaged product in the second half of FY18.

The new production facility will be unique in that it will house the Drug Substance, Drug Product, Primary and Secondary Packaging and QC processes all under one roof.

NINLARO was approved in November 2015 by the U.S. Food and Drug Administration (FDA). It is the first and only once-weekly oral proteasome inhibitor launched in the U.S. for the treatment of patients with multiple myeloma who have received at least one prior therapy, enabling an all-oral proteasome inhibitor-based triplet treatment regimen for the first time. Additionally, NINLARO® was approved by the Japanese Ministry of Health, Labour and Welfare in March 2017 and launched in May as the first oral proteasome inhibitor in Japan, indicated in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma.

About Author

editor

editor

Related Articles

New Subscriber





Subscribe Here



Advertisements



















National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4